Claritev (CTEV) AI Stock Analysis

• Market Cap: $919.79M
• Dividend Yield: N/A
• Average Volume (3M): 136.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: -2.03%
• EPS Growth: 43.59%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -3.81
• Shares Outstanding: 16,474,834
• 10 Day Avg. Volume: 110,608
• 30 Day Avg. Volume: 136,205
• PEG Ratio: >-0.01
• Price to Book (P/B): 5.61
• Price to Sales (P/S): 0.51
• P/FCF Ratio: -44.88
• Enterprise Value/Market Cap: 5.79
• Enterprise Value/Revenue: 5.69
• Enterprise Value/Gross Profit: 9.10
• Enterprise Value/Ebitda: 280.82
• 1Y Price Target: $68.00
• Price Target Upside: 21.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 54 Neutral
• Price Target: $56.00 ▲(0.30% Upside)

Claritev's stock score is primarily impacted by its poor financial performance, characterized by significant losses and high leverage. While technical analysis indicates strong momentum, overbought conditions could lead to a pullback. The negative P/E ratio and lack of dividend yield further weigh on the overall score.

Claritev Business Overview & Revenue Model

Company Description

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.

How the Company Makes Money

Claritev generates revenue primarily through a subscription-based model for its software applications, offering tiered pricing plans based on the features and services utilized by its clients. Additionally, the company earns income through implementation services, where it assists businesses in integrating its solutions into their existing systems. Claritev also engages in strategic partnerships with telecommunications providers and technology firms to expand its market reach, which contributes to its revenue through joint ventures and co-branded product offerings. Furthermore, the company may earn revenue from consultancy services, providing expert advice and tailored solutions to enhance operational efficiency for its clients.

Claritev Financial Statement Overview

Summary

Claritev faces significant financial challenges, with a negative net profit margin and high leverage. The negative equity and cash flow issues further exacerbate financial instability, posing risks to long-term sustainability.

Income Statement

Claritev's income statement reveals significant challenges. The TTM data shows a negative net profit margin of -126.96%, indicating substantial losses. Revenue growth is positive at 87.3% TTM, but this is overshadowed by negative EBIT and EBITDA margins, suggesting operational inefficiencies. Historical data shows a declining trend in profitability, with consistent negative net income over the years.

Balance Sheet

The balance sheet highlights financial instability, with a concerning debt-to-equity ratio of 312.43 in the TTM period, reflecting high leverage. Stockholders' equity is negative, indicating potential solvency issues. The return on equity is also negative, suggesting poor returns for shareholders. These factors point to significant financial risk.

Cash Flow

Cash flow analysis shows mixed results. The operating cash flow to net income ratio is positive at 0.15 TTM, indicating some cash generation capability. However, free cash flow is negative, and its growth rate is declining, which could impact future liquidity. The free cash flow to net income ratio is also negative, reflecting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	935.54M	930.62M	961.52M	1.08B	1.12B	937.76M
Gross Profit	585.09M	691.22M	726.06M	875.62M	942.31M	619.09M
EBITDA	18.96M	-1.01B	651.93M	158.32M	814.99M	192.41M
Net Income	-663.37M	-1.65B	-91.70M	-572.91M	102.08M	-520.56M
Balance Sheet
Total Assets	5.07B	5.15B	6.96B	7.37B	8.22B	8.28B
Cash, Cash Equivalents and Short-Term Investments	56.39M	16.85M	71.55M	334.05M	185.33M	126.75M
Total Debt	4.57B	4.54B	4.57B	4.78B	4.93B	4.61B
Total Liabilities	5.11B	5.07B	5.26B	5.58B	5.88B	5.73B
Stockholders Equity	-39.91M	84.02M	1.71B	1.79B	2.34B	2.56B
Cash Flow
Free Cash Flow	-55.01M	-10.51M	62.87M	282.63M	320.10M	306.56M
Operating Cash Flow	70.61M	107.62M	171.72M	372.36M	404.69M	377.37M
Investing Cash Flow	-125.62M	-118.12M	-249.79M	-104.45M	-228.38M	-210.84M
Financing Cash Flow	63.13M	-41.31M	-180.99M	-115.74M	-114.68M	-61.60M

Claritev Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 55.83
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Neutral. The current price of 55.83 is below the 20-day moving average (MA) of 67.10, below the 50-day MA of 56.66, and above the 200-day MA of 31.19, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 37.25 is Neutral, neither overbought nor oversold. The STOCH value of 1.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTEV.

Claritev Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSTM	75 Outperform	859.59M	43.59	5.80%	0.42%	3.50%	13.99%
NUTX	71 Outperform	499.85M	7.56	35.65%	―	141.25%	0.00%
CTEV	54 Neutral	$919.79M	―	-235.47%	―	-2.03%	43.59%
DH	52 Neutral	582.75M	-1.54	-74.11%	―	-5.24%	23.59%
EVH	51 Neutral	1.00B	-5.32	-18.04%	―	-6.71%	-71.40%
HCAT	49 Neutral	197.75M	-1.86	-28.81%	―	5.55%	-0.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Claritev Corporate Events

Claritev Releases New Investor Presentation on Website

On September 3, 2025, Claritev Corporation announced the availability of a new slide presentation for investors on its website. This presentation, which is part of a regulatory compliance effort, outlines forward-looking statements about the company’s strategic and financial plans, including transformation and expansion initiatives. The presentation also discusses non-GAAP financial measures such as EBITDA and Free Cash Flow, which are used to evaluate the company’s performance and operational efficiency. The announcement highlights the company’s focus on strategic growth and financial performance, although it also acknowledges potential risks and uncertainties that could impact future results.